Administrative information
Title {1} | Preoperative smoking cessation program in patients undergoing intermediate to high-risk surgery: a monocentric, randomized, single-blinded, controlled trial |
Trial registration {2a and 2b}. | BASEC #2021-02004; Registration on Clinical Trials: NCT05192837 https://clinicaltrials.gov/ct2/show/NCT05192837 on January 14, 2022 |
Protocol version {3} | Version 3, 01/05/2022. |
Funding {4} | This study is funded by the Swiss Cancer League (HSR-5217-11-2020) and regular reporting is required but investigators are analyzing the data independently. |
Author details {5a} | Christian D Fankhauser1, 2, Andres Affentranger1, Beatrice Cortonesi1, Urs Jeker2, Markus Gass2, Fabrizio Minervini2, Georg Jung2, Corina Christmann2, Christine Brambs2, Milo A. Puhan1, Ulrike Held1* 1 Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland 2 University of Lucerne, Lucerne, Switzerland *corresponding author |
Name and contact information for the trial sponsor {5b} | PD Dr. med. Christian Fankhauser Spitalstrasse 6000 Lucerne Switzerland christian.fankhauser@luks.ch +41 41 205 11 11 |
Role of sponsor {5c} | Dr. Fankhauser is responsible for design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication and has the ultimate authority over any of these activities. |
Introduction
Background and rationale {6a}
Objectives {7}
Hypothesis and primary objective
Trial design {8}
Methods: Participants, interventions, and outcomes
Study setting {9}
Eligibility criteria {10}
Inclusion criteria
-
Patient undergoing surgery in one of the following departments: Abdominal surgery, thoracic surgery, urology, gynaecology, vascular surgery or head and neck surgery
-
Date of surgery >4 weeks planned after date of listing for surgery or discussion by tumor board
-
Current smokers, defined as daily smoking of at least one cigarette, cigar, or pipe
-
Age ≥ 18 years
-
Able to give signed written informed consent
Exclusion criteria
-
Consumption of illegal drugs
-
Alcohol dependency defined as preexisting alcohol-related disorders (eg. alcoholic psychosis, alcohol abuse, alcohol polyneuropathy, degeneration of the nervous system due to alcohol, alcoholic myopathy, alcoholic liver disease)
-
Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia
Who will take informed consent? {26a}
Additional consent provisions for collection and use of participant data and biological specimens {26b}
Interventions
Explanation for the choice of comparators {6b}
Intervention description {11a}
-
Informative content about advantages of smoking cessation [15] using information leaflets along with decision support
-
Scheduling service for a motivational interview by a TSS in the office to provide educational and motivational content, explain the magnitude and profile of nicotine dependence and implement a treatment plan [16]
-
For participants willing to quit smoking a preoperative quit day will be scheduled after the first intervention meeting 2–3 weeks before surgery. Time of a preoperative quit day may vary between patients, since our smoking intervention focuses on as early quit attempts as possible. Therefore, there will be a variety in patients with one or more quit attempts, with or without success, and patients who quit smoking in the postoperative period, only.
-
Patients will be encouraged by a TSS to use nicotine replacement with patches/gums/pills at their own discretion. For smokers of 20 cigarettes per day or more, a 4-week supply of 21mg/day, 2-week supply of 14 mg/day and a 2-week supply of 7 mg/days patches will be provided. Patients who smoke between 10 and 20 cigarettes per day will receive a 4-week supply of 14 mg/day and a 4-week supply of 7 mg/day. Smokers of <10 cigarettes per day will be supplied with a 4- to 8-week supply of 7-mg/day patches. Bupropion or Varenicillin will be provided on an individual basis (all costs are covered by the patient’s insurance).
Criteria for discontinuing or modifying allocated interventions {11b}
Strategies to improve adherence to interventions {11c}
Relevant concomitant care permitted or prohibited during the trial {11d}
Provisions for post-trial care {30}
Outcomes {12}
Participant timeline {13}
Sample size {14}
Recruitment {15}
Assignment of interventions: allocation
Sequence generation {16a}
Concealment mechanism {16b}
Implementation {16c}
Assignment of interventions: Blinding
Who will be blinded {17a}
Procedure for unblinding if needed {17b}
Data collection and management
Plans for assessment and collection of outcomes {18a}
Plans to promote participant retention and complete follow-up {18b}
Data management {19}
Confidentiality {27}
Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}
Statistical methods
Statistical methods for primary and secondary outcomes {20a}
Interim analyses {21b}
Methods for additional analyses (e.g. subgroup analyses) {20b}
Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}
Plans to give access to the full protocol, participant level-data and statistical code {31c}
Oversight and monitoring
Composition of the coordinating centre and trial steering committee {5d}
Composition of the data monitoring committee, its role and reporting structure {21a}
Adverse event reporting and harms {22}
-
Results in death or is life-threatening,
-
Requires in-patient hospitalisation or prolongation of existing hospitalisation,
-
Results in persistent or significant disability or incapacity, or
-
Causes a congenital anomaly or birth defect